HLA’s future impact on allogeneic cell therapy development

From cell bank creation to maximizing population coverage

Maintaining business continuity during COVID-19

Lessons learned will have positive impacts beyond the pandemic

6 Considerations When Evaluating Cell Sourcing Vendors

Including questions to ask potential cell sourcing partners

Scaling cell therapy supply chains during a pandemic

Achieving donor pool sustainability and cell therapy supply chain success

The role of ‘super donors’ in cell therapy scalability

Why reliance on a small subset of donors could introduce risk for companies

HLA matching could bring more allogeneic cell therapies to market, faster

An expert opinion on HLA matching relevance for allogeneic cell therapies

Quality Starting Material: The Driving Force Behind Life-Saving Cell Therapies

By Jamie Margolis, PhD, Senior Vice President of Donor Services, NMDP/Be The Match

Overcoming challenges to cellular starting material collection

Q&A with the Be The Match BioTherapies Collection Network Liaison team

An opportunity to impact the future of medicine

As told by Leah, Be The Match BioTherapies® allogeneic donor